Long-term safety and efficacy of armodafinil in bipolar depression: A 6-month open-label extension study
Autor: | Mark A. Frye, Terence A. Ketter, Nicholas Gross, Jess Amchin |
---|---|
Rok vydání: | 2016 |
Předmět: |
Adult
Male medicine.medical_specialty Bipolar Disorder Bipolar I disorder Modafinil Anxiety Placebo Akathisia 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Double-Blind Method Sleep Initiation and Maintenance Disorders Internal medicine medicine Humans Bipolar disorder Benzhydryl Compounds Psychiatry Aged Armodafinil Headache Wakefulness-Promoting Agents Middle Aged medicine.disease 030227 psychiatry Psychiatry and Mental health Clinical Psychology Treatment Outcome Mood chemistry Tolerability Female medicine.symptom Psychology Mania 030217 neurology & neurosurgery |
Zdroj: | Journal of Affective Disorders. 197:51-57 |
ISSN: | 0165-0327 |
DOI: | 10.1016/j.jad.2016.02.050 |
Popis: | Background Safe/well-tolerated treatments for bipolar I depression remain limited. We assessed safety/tolerability of adjunctive open-label armodafinil, a wakefulness-promoting agent evaluated in 3 acute, controlled efficacy studies with variable efficacy results. Methods Completers of three 8-week, double-blind, placebo-controlled adjunctive armodafinil studies (150–200 mg/day added to ongoing stable maintenance doses of 1 or 2 protocol-defined mood stabilizers) in bipolar I depression could enter this 6-month, open-label extension study. Objectives included evaluation of safety/tolerability (primary) and efficacy (secondary). Results 867 patients enrolled; 863 received ≥1 dose of armodafinil and 506 (58%) completed the 6-month study. Headache, insomnia, and anxiety were the most common adverse events (AEs) reported, whereas akathisia, nausea, sedation/somnolence, and weight increase were uncommon. Mean measures assessing emergence of mania, anxiety, insomnia, or suicidality showed no worsening. Discontinuations due to AEs occurred in 57 (7%) patients. Serious AEs occurred in 27 (3%) patients and were considered treatment-related in 8 (1%) patients. Depressive symptoms improved over the 6 months, as did patient functioning. Limitations Lack of placebo control. Conclusions Adjunctive armodafinil was generally safe and well tolerated over 6 months of open-label treatment at 150–200 mg/day when taken with protocol-defined mood stabilizers for bipolar I depression. This 6-month open-label study suggested that armodafinil augmentation of bipolar maintenance therapies may have a favorable risk profile and may improve depressive symptoms in some patients with bipolar I depression. |
Databáze: | OpenAIRE |
Externí odkaz: |
Pro tento záznam nejsou dostupné žádné jednotky.